LC‐MS/MS method for the quantification of new psychoactive substances and evaluation of their urinary detection in humans for doping control analysis
- 16 January 2020
- journal article
- research article
- Published by Wiley in Drug Testing and Analysis
- Vol. 12 (6) , 785-797
Abstract
The constant legal adaptation of new psychoactive substances (NPS), challenges their evaluation in different fields. In sports, NPS are prohibited in competition with a reporting limit (RL) of 50 ng/mL for the parent compound or a metabolite. However, there is a lack of comprehensive methodologies and excretion studies for monitoring NPS. This work aims to develop an analytical methodology for the NPS quantification and to evaluate the suitability of monitoring the urinary parent stimulants after NPS misuse. A method for the quantification of 14 common NPS was developed and validated. The method was found to be linear in the range 1–1000 ng/mL, and was shown to be accurate and precise. A lowest limit of quantification (LLOQ) of 1 ng/mL was established for all analytes except for benzylpiperazine (5 ng/mL). The method was able to confirm the identity of the analytes at the LLOQ for most NPS. The methodology was applied to the quantification of the parent compound in urine samples collected from an observational study where several healthy volunteers (n ≥ 6 per drug) ingested active doses of mephedrone (MEPH), methylone (MDMC), 2,5‐dimetoxy‐4‐ethylphenetylamine (2C‐E), or 6‐(2‐aminopropyl)benzofuran (6‐APB). It was observed that for MDMC and 6‐APB, the quantification of the urinary parent drug at the current RL is a proper strategy for detecting their misuse. However, this strategy seems to be insufficient for evaluating MEPH and 2C‐E misuse. Monitoring the most abundant metabolite of MEPH (4′‐carboxy‐MEPH) and the reduction of the RL to 10 ng/mL for the 2C‐E evaluation are proposed.Keywords
Funding Information
- European Commission (HOME/2014/JDRU/AG/DRUG/7082)
- Instituto de Salud Carlos III (ISCIII, FIS‐FEDER, FISPI17/01962)
- Partnership for Clean Competition (Screening Emerging Stimulants by Analytical and Me)
- Instituto de Salud Carlos III (RD16/0017/003)
This publication has 25 references indexed in Scilit:
- Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography–high resolution mass spectrometry and library matchingJournal of Chromatography A, 2015
- Simple and rapid screening procedure for 143 new psychoactive substances by liquid chromatography‐tandem mass spectrometryDrug Testing and Analysis, 2015
- Screening method for stimulants in urine by UHPLC‐MS/MS: identification of isomeric compoundsDrug Testing and Analysis, 2015
- Mass Spectrometric Evaluation of Mephedrone In Vivo Human Metabolism: Identification of Phase I and Phase II Metabolites, Including a Novel Succinyl ConjugateDrug Metabolism and Disposition, 2015
- Simultaneous detection of 93 conventional and emerging drugs of abuse and their metabolites in urine by UHPLC-MS/MSJournal of Chromatography B, 2014
- Dilute-and-shoot-liquid chromatography-mass spectrometry for urine analysis in doping control and analytical toxicologyTrAC Trends in Analytical Chemistry, 2014
- Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometryAnalytical and Bioanalytical Chemistry, 2013
- Multicomponent LC–MS/MS screening method for detection of new psychoactive drugs, legal highs, in urine—Experience from the Swedish populationJournal of Chromatography B, 2013
- Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamicsPsychopharmacology, 2013
- Psychoactive “bath salts”: Not so soothingEuropean Journal of Pharmacology, 2013